If you have been reading about GHRH receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
=== Bone morphogenetic proteins === Bone morphogenetic proteins (BMPs) are proteins that are made of acidic polypeptides and belongs to the TGF-B family. BMPs promote the regeneration of bone tissue and cartilage. BMP exhibits osteoinductive activity. Osteoinductive activity leads to bone formation, activates mesenchymal cells to transform into osteoblasts which ultimately yield bone formation. BMP targets and binds to mesenchymal cells and activates a transmembrane serine/threonine kinase receptor which will lead to the phosphorylation of molecules called SMADS. SMADS are transcription factors that will induce osteoblast growth.
Jung's research and personal vision, however, made it difficult to follow his older colleague's doctrine, and they parted ways. This division was painful for Jung and resulted in the establishment of Jung's analytical psychology as a comprehensive system separate from psychoanalysis. Among the central concepts of analytical psychology is individuation—the lifelong psychological process of differentiation of the self out of each individual's conscious and unconscious elements. Jung considered it to be the main task of human development. He created some of the best-known psychological concepts, including synchronicity, archetypal phenomena, the collective unconscious, the psychological complex, and extraversion and introversion. His treatment of American businessman and politician Rowland Hazard in 1926 with his conviction that alcoholics may recover if they have a "vital spiritual (or religious) experience" played a crucial role in the chain of events that led to the formation of Alcoholics Anonymous. Jung was an artist, craftsman, builder, and prolific writer. Many of his works were not published until after his death, and some remain unpublished.
== Personal life == Austin played college football at the University of North Texas. Austin married his high school girlfriend Kathryn Burrhus on November 24, 1990. However, he later pursued a relationship with English wrestling manager Jeanie Clarke, with whom he was working. His marriage to Burrhus was annulled on August 7, 1992, while he was in Japan and he married Clarke on December 18, on his 28th birthday. They had two daughters before divorcing in 1999. Austin also adopted Clarke's daughter from a previous relationship with Chris Adams. Austin's adoptive daughter was married to fellow professional wrestler Adam Bryniarski until his death in 2022. In 1998, Austin was the recipient of Hamilton, Ontario's "Key to the City", he is one of two people to ever be bestowed the honor, the other being the basketball player Shai Gilgeous-Alexander. That same year on September 1, the city of Lowell, Massachusetts declared that date Stone Cold day along with naming a street after him for the day. The date March 16 is commonly associated with Austin due to the date matching up with his wrestling catchphrase "Austin 3:16". On September 13, 2000, Austin married wrestling manager Debra Marshall. On June 15, 2002, Marshall called the police to the couple's home. She told officers that Austin had hit her and then stormed out of the house before police arrived. An arrest warrant was issued by the Bexar County district attorney's office on August 12 and Austin turned himself in the following day, at which point he was charged with domestic abuse.
Sources: en.wikipedia.org
==== Monte Carlo and simulated annealing ==== Monte Carlo is one of the most widely used algorithms for protein design. In its simplest form, a Monte Carlo algorithm selects a residue at random, and in that residue a randomly chosen rotamer (of any amino acid) is evaluated. The new energy of the protein, Enew is compared against the old energy Eold and the new rotamer is accepted with a probability of:
==== Comparison with other antidepressants ==== In general, sertraline efficacy is similar to that of other antidepressants. For example, a meta-analysis of 12 new-generation antidepressants showed that sertraline and escitalopram are the best in terms of efficacy and acceptability in the acute-phase treatment of adults with depression. Comparative clinical trials demonstrated that sertraline is similar in efficacy against depression to moclobemide, nefazodone, escitalopram, bupropion, citalopram, fluvoxamine, paroxetine, venlafaxine, and mirtazapine. Sertraline may be more efficacious for the treatment of depression in the acute phase (first four weeks) than fluoxetine. There are differences between sertraline and some other antidepressants in their efficacy in the treatment of different subtypes of depression and in their adverse effects. For severe depression, sertraline is as good as clomipramine but is better tolerated. Sertraline appears to work better in melancholic depression than fluoxetine, paroxetine, and mianserin and is similar to the tricyclic antidepressants such as amitriptyline and clomipramine. In the treatment of depression accompanied by OCD, sertraline performs significantly better than desipramine on the measures of both OCD and depression. Sertraline is equivalent to imipramine for the treatment of depression with co-morbid panic disorder, but it is better tolerated. Compared with amitriptyline, sertraline offered a greater overall improvement in quality of life of depressed patients.
During the 1990s, Brazil saw a surge of critical and commercial success with films such as O Quatrilho (Fábio Barreto, 1995), O Que É Isso, Companheiro? (Bruno Barreto, 1997) and Central do Brasil (Walter Salles, 1998), all of which were nominated for the Academy Award for Best Foreign Language Film, the latter receiving a Best Actress nomination for Fernanda Montenegro. The 2002 crime film City of God, directed by Fernando Meirelles, was critically acclaimed, scoring 90% on Rotten Tomatoes, being placed in Roger Ebert's Best Films of the Decade list and receiving four Academy Award nominations in 2004, including Best Director. Notable film festivals in Brazil include the São Paulo and Rio de Janeiro International Film Festivals and the Gramado Festival. The film I'm Still Here, directed by Walter Salles, was nominated for Best Actress (Torres) and Best Picture at the 97th Academy Awards, and won Best International Feature Film, becoming the first-ever Brazilian produced film to win an Academy Award. The film The Secret Agent had its world premiere at the main competition of the 2025 Cannes Film Festival on 18 May 2025, where it won the Best Actor prize for Wagner Moura, the Best Director prize for Mendonça and the FIPRESCI Prize. It received further widespread critical acclaim.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.